Prashant Dogra is an Assistant Research Professor for the Mathematics in Medicine Program at Houston Methodist Research Institute specializing in mathematical and computational modeling of complex diseases and therapeutic interventions. He leads interdisciplinary research integrating multiscale mechanistic modeling, quantitative systems pharmacology, and data science to predict in vivo disease dynamics, optimize drug delivery, and support therapeutic development. His work advances the fields of cancer therapeutics, infectious disease vaccines, and nanomedicine by providing innovative modeling tools to accelerate clinical translation. He is particularly enthusiastic about integrating artificial intelligence with mechanistic modeling approaches and currently serves as Principal Investigator on an NIH R01 grant focused on developing AI-integrated mechanistic models to advance nanoparticle-based drug delivery systems.

Eleni Caratzas (Karatza), MSc, PhD, is a Principal Scientist II at J&J IM/Janssen R&D. She completed her undergraduate and master’s degrees in pharmacy at the University of Athens, Greece. Following her studies, she started working as a scientist-consultant at a pharmaceutical consulting firm. After earning her PhD, she started her postdoctoral fellowship with the UNC Eshelman School of Pharmacy and GSK. Dr. Karatza has published over 25 peer-reviewed articles and book chapters in the field of clinical pharmacology and pharmacometrics. An active ISoP member since 2018, she has supported various ISoP and ACoP initiatives and she was awarded the ISoP Unsung Hero Award in 2024.

Martin obtained his PhD in Pharmacometrics from Uppsala University. He has 20+ years of drug development experience in areas such as metabolic disorders, autoimmune disease, infectious disease, hematological disorders etc. In 2012 Martin co-founded the consulting company Pharmetheus AB. In the consultant role he has been engaged as strategic advisor on behalf of multiple clients and acted as the main responsible consultant for 50+ pharmacometric data analysis projects on behalf of more than 20 different clients. The projects have ranged from pre-clinical translational projects to submission ready large-scale phase III PKPD analysis. These analyses have among other things contributed to 5+ successful NDA filings. 

Gianluca obtained an M.Sc. in Biomedical engineering from University of Bologna, Italy, and Ph.D. in Bioengineering from the New University of Lisbon, Portugal. He is an expert in quantitative systems pharmacology (QSP) modelling spanning therapeutic areas such as oncology and immuno-inflammation. He has worked as a Senior Modeler at the Fondazione Microsoft Research – University of Trento Centre for Computational and Systems Biology. During his time at Pharmetheus he has among other things contributed to the development of a QSP framework for drug immunogenicity following subcutaneous administration.

Jeffry Florian serves as an Associate Director in the Division of Applied Regulatory Science (DARS), Office of Clinical Pharmacology, Office of Translational Sciences at CDER/FDA and has worked at FDA for 15 years spanning multiple roles. In his current role, he supervises DARS teams involve in clinical and computational applied research. Activities include using in silico tools to explain emerging safety signals based on both known and predicted mechanisms, developing text-mining algorithms to quickly identify information to support labeling and policy development, and application of systems modeling approaches for topics such as CiPA (Comprehensive in vitro Proarrhythmia Assay), opioid overdose, and cannabidiol liver safety. Jeffry received his PhD in Chemical Engineering from the University of Pittsburgh in 2007.

Katie Maass is a Senior Principal Scientist in the Clinical Pharmacology department at Genentech, focusing on ophthalmology programs. She has experience on cross-functional drug development teams supporting programs in the pre-IND stage through post-approval. She has contributed to clinical study designs, regulatory interactions, clinical study data analysis and interpretation, pharmacokinetic and pharmacodynamics modeling and simulation, and project team decision making. Katie received her BS in chemical engineering at the University of Texas at Austin and PhD in chemical engineering at MIT.

Lauren Price, PharmD, is a Clinical Pharmacology Team Lead in the Office of Cancer Pharmacology II, Office of Clinical Pharmacology, US Food & Drug Administration. She obtained a PharmD from the University of Washington School of Pharmacy and subsequently completed an oncology fellowship at the University of North Carolina Eshelman School of Pharmacy. Lauren joined the FDA in 2018 where she reviews and provides regulatory and scientific advice on IND, NDA, and BLA submissions for oncology products.

Jing Liu, PhD, is currently a Senior Director of Clinical Pharmacology at Pfizer Research and Development. Dr. Liu is an influential leader in innovative model-informed drug discovery and development with over 25+ years of experience across multiple disease areas, drug modalities and all stages of drug development. She has authored 150+ scientific manuscripts, abstracts and book chapters, and has been an invited speaker/Co-Chair at international scientific meetings including scientific exchanges on accelerating pediatric drug development with PMDA in Japan and NMPA in China. Dr. Liu is currently a member of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) Board of Directors, and has held leadership roles on various committees, task forces, and ASCPT Network and Community. She is also a founding member of International Society of Pharmacometrics (ISOP) and the Abstract Chair for 2014 American Conference of Pharmacometrics (ACOP). Dr. Liu is the Past-Chair and a member of the International Consortium for Innovation and Quality (IQ) Clinical Pharmacology Pediatrics Working Group to advance innovative and efficient pediatric drug development.

Dr. Cédric Scherer (he/him) is a computational ecologist turned independent data visualization professional. Combining research expertise with a passion for data and design, he helps organizations, research teams, and businesses communicate insights through engaging visualizations, reports, and presentations. Specializing in bespoke, code-driven designs—from clear and effective to artistic and unconventional—Cédric has created visualizations across various disciplines and regularly teaches data visualization principles, R, and ggplot2.

Rong is a research scientist at Certara USA Inc’s Data Sciences Division Phoenix NLME group. His responsibility involves maintaining, improving, and developing the existing and new computational and statistical algorithms for Phoenix NLME software. Rong got his nuclear physics PhD at Arizona State University in 2020. The PhD focused on large-scale quantum Monte Carlo simulations. Prior to join Certara in 2023, Rong was a postdoctoral research fellow at Children’s Hospital Los Angeles where he developed high performance parametric and nonparametric algorithms for population pharmacokinetics/pharmacodynamics (PK/PD) modeling.

Christian Bartels studied molecular biology at the Biocentre in Basel to focus then on data analysis, modeling and simulation. After some notable contributions to proteomics, protein structure determination, peptide folding and drug design, he specialized into pharmacometrics. Since 2009, Christian works in the pharmacometrics modeling and simulation group from Novartis supporting compounds across the portfolio.

Manuela Zimmermann is a Principal Pharmacometrician at Novartis, supporting the clinical development of new compounds primarily in the oncology therapeutic area. Before joining the Pharmacometrics Department, she worked on type-I error controlled exploratory variable selection as part of the Advanced Methodology and Data Science group at Novartis. Manuela holds a Ph.D in Biophysics and Biophysical Chemistry from the University of Cambridge. Her thesis focused on developing quantitative methods to investigate stochastic phenomena linked to Alzheimer’s disease.